Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 5/20 | 0.57 |
| ▸ | MMP9 | P14780 | 4/20 | 0.57 |
| ▸ | MMP3 | P08254 | 3/20 | 0.57 |
| ▸ | MMP7 | P09237 | 3/20 | 0.57 |
| ▸ | MMP13 | P45452 | 5/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 6/20 | 0.42 |
| ▸ | F13A1 | P00488 | 4/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | TGM1 | P22735 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24762629 | 0.89 | MMP1 (0.55) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL17800494 | 0.89 | MMP1 (0.53) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL2441360 | 0.84 | MMP1 (0.64) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL15919232 | 0.84 | MMP1 (0.46) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL15919233 | 0.84 | MMP1 (0.46) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL5445749 | 0.83 | CA1 (0.48) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL5436999 | 0.83 | MMP1 (0.68) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL22089008 | 0.80 | MMP1 (0.53) | MMP1MMP9MMP3MMP7MMP13 | |
| SCHEMBL4408409 | 0.80 | MMP1 (0.44) | MMP1MMP9MMP3MMP7TGM2 | |
| SCHEMBL190647 | 0.79 | NR1H2 (0.47) | MMP1MMP9MMP3MMP7GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | MMP1 4632/4885MMP9 3531/4885MMP3 4253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.